CellaVision delivers 1,000th digital cell morphology system to Southampton General Hospital, England
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, has delivered its 1,000th CellaVision® DM analyzer. The achievement confirms the company's position as a market leading supplier, and is an important milestone in the company's ten-year sales history.
The order from Southampton General Hospital came in July through the distributor Sysmex Europe, CellaVision's partner in Europe for 10 years, and was delivered to the customer site this week.
"We are proud of this significant achievement to have placed 1,000 systems globally since our sales began in 2001," stated Yvonne Mårtensson, CEO of CellaVision. "With customers in more than 40 countries, we are recognized for product excellence and adding value to the lab. This strengthens us in our goal to become the global standard for digital cell morphology in hematology. Many thanks to all our customers and partners who have helped us to build our market through confidence in CellaVision and our products.
The global market for CellaVision's products is large, and CellaVision is working in many countries, both through strong partners as well as its own subsidiaries. CellaVision's target group is hospitals with more than 200 beds and commercial laboratories that at present perform analyses manually using a microscope. The demand for CellaVision's products is strong and is due to increased efficiency and quality requirements in the healthcare market, particularly in Europe and North America. Growing staff shortages in laboratory operations make CellaVision's automated products a necessity in many labs.
CellaVision was founded in 1994 to develop automated microscopic analysis. The idea came from the then medical student Christer Fahraeus, now one of Sweden's best known entrepreneurs. 1997, CellaVision recruited its first employees and as early as in 2000 the first analyzer was launched in Europe. The year after CellaVision found its first customer, the University Hospital in Malmo, and the instrument was cleared by the FDA. Since then it has strengthened its product portfolio, grown its customer base globally and since 2007 CellaVision continues expanding, profitably. 2010 turnover was 132 million SEK with North America accounting for 50% of sales, Europe for 40% and the rest of the world for 10%.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: email@example.com
CellaVision is an innovative, global medical technology company that develops and sells best-in-class systems for the routine analysis of blood and other body fluids. These analyses often provide critical results used in the diagnosis of a variety of illnesses such as infection and cancer. CellaVision's products reduce manual laboratory work, standardize results and support an efficient laboratory workflow. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy. In 2010, net sales were 132 MSEK and sales continue to grow with the target to increase by at least 15 % per year over an economic cycle. CellaVision has its head office in Lund, Sweden, and subsidiaries in the US, Canada and Japan. The company share is listed on Nasdaq OMX Stockholm, Small Cap. Read more at www.cellavision.com.